MacroGenics, Inc.

Healthcare · Biotechnology · United States

Last price 2.38 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 151.61M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG...